Giant Biogene Holding Co., Ltd. filed its Monthly Return for Equity Issuer for the period ended 31 March 2026, showing no changes in authorised or issued share capital during the month.
Authorised / Registered Capital • Authorised capital held at 5.00 billion ordinary shares with a par value of USD 0.00001 each, translating to an unchanged registered capital of USD 50,000.
Issued Shares and Public Float • Issued shares (excluding treasury shares) closed March at 1.07 billion, identical to the prior-month figure. • The company reported zero treasury shares. • Public float met the Main Board’s 25% threshold.
Share Option Activity • Under the 2023 Share Option Scheme adopted on 17 August 2023, 11.60 million options remained outstanding; no options were exercised, cancelled or lapsed in March. • The scheme still allows up to 80.22 million shares to be granted in future, while no new shares were issued and no funds were raised through option exercise during the month.
Share Repurchase Status • The filing reiterates the 9.20 million shares repurchased on 13 June 2025 that remain pending cancellation; however, there was no movement in March 2026.
Compliance Confirmation • Management affirmed full compliance with listing rules and other regulatory requirements, and confirmed receipt of all monies due related to any prior share issues.
Overall, Giant Biogene recorded a stable capital structure in March 2026, with no dilution or treasury activity and maintained regulatory public-float compliance.
Comments